# Mission Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mission-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.missionbio.com
- Total disclosed funding: $122M
- Latest round: Series C (Jul 2, 2020)
- Investors on record: 15

## About

Based in the US, Mission Bio, Inc. specializes in single-cell technology that enhances cell therapy development and offers vital insights into cancer mechanisms, catering primarily to cancer researchers and pharmaceutical companies.Mission Bio, Inc. was founded in 2014 and is headquartered in San Francisco, US. The company focuses on single-cell analysis to improve cell therapies and has raised a total of USD 70.00 mn through various funding rounds, including the most recent Venture Debt round of USD 40.00 mn on June 1, 2022, from Armentum Partners. Adam Sciambi is the founder of the company, which has completed 11 different deals in its history.Mission Bio specializes in single-cell technology that enhances the development of cell therapies and provides detailed insights into cancer mechanisms. Their core product, the Tapestri Single-cell Multiomics Solution, allows researchers to analyze single nucleotide variation (SNV), copy number variation (CNV), and protein data from individual cells, particularly in the context of diseases like multiple myeloma. This platform addresses critical research needs by revealing clonal heterogeneity, which plays a significant role in disease progression and treatment responses. Mission Bio primarily serves cancer researchers and pharmaceutical companies involved in drug development and clinical research, offering end-to-end support from initial studies to commercial manufacturing and release testing. Their products are marketed across various global regions, focusing on biotech hubs in North America, Europe, and Asia, where precision medicine and advanced therapeutic solutions are in high demand.Mission Bio generates revenue through a combination of direct sales and partnerships with pharmaceutical companies and research institutions. Their business model involves subscriptions for access to their technology, alongside transactional sales of the Tapestri platform and related services. Clients typically engage in long-term collaborations that include the procurement of single-cell technology for specific research projects or drug development initiatives. The revenue structure is supported by agreements that facilitate the delivery of ongoing support and assay development services tailored to the unique needs of each client. Specific pricing details for the Tapestri Single-cell Multiomics Solution are not disclosed, but offerings are positioned within the premium range, reflective of the advanced capabilities and insights provided by their proprietary technology.In the coming years, Mission Bio plans to expand its product offerings with new innovations in single-cell technology aimed at enhancing precision medicine solutions. The recent funding round of USD 40.00 mn will be utilized to accelerate product development and support market entry into new regions, specifically targeting expansion in Europe and Asia by the end of 2023. This initiative is expected to strengthen the company's presence in vital biotech hubs and foster collaborations with more pharmaceutical partners.

## Funding rounds

- Series C, Jul 2, 2020, $70M — Mayfield Fund, Novo Holdings, Agilent Technologies, Cota Capital, Soleus Capital
- Series B, Jun 29, 2018, $28M — Mayfield Fund, Agilent Technologies, Sand Hill Angels, Cota Capital, Silicon Valley Social Venture Fund, Foothill Ventures, Mighty Capital, Lam Capital
- Series A, Oct 17, 2017, $10M — Mayfield Fund, Tech Coast Angels, Life Science Angels, Inc., Keiretsu Capital, Stanford-StartX Fund
- Series A, Jun 9, 2017, $13M — Life Science Angels, Inc., Sand Hill Angels, Cota Capital
- Seed, Jul 1, 2016 — Fusion Fund

## Investors

- Fusion Fund (https://capitalatlas.ai/funds/fusion-fund) — Seed
- Life Science Angels, Inc. — Series A
- Sand Hill Angels (https://capitalatlas.ai/funds/sand-hill-angels) — Series A, Series B
- Cota Capital (https://capitalatlas.ai/funds/cota-capital) — Series A, Series B, Series C
- Mayfield Fund (https://capitalatlas.ai/funds/mayfield-fund) — Series A, Series B, Series C
- Tech Coast Angels — Series A
- Keiretsu Capital (https://capitalatlas.ai/funds/keiretsu-capital) — Series A
- Stanford-StartX Fund — Series A
- Agilent Technologies — Series B, Series C
- Silicon Valley Social Venture Fund — Series B
- Foothill Ventures (https://capitalatlas.ai/funds/foothill-ventures) — Series B
- Mighty Capital (https://capitalatlas.ai/funds/mighty-capital) — Series B
- Lam Capital (https://capitalatlas.ai/funds/lam-capital) — Series B
- Novo Holdings — Series C
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series C